135 related articles for article (PubMed ID: 3948186)
1. Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
Winograd B; Vermorken JB; ten Bokkel Huinink WW; Simonetti G; Gall HE; Knobf MK; van der Vijgh WJ; McVie JG; Pinedo HM
Cancer Res; 1986 Apr; 46(4 Pt 2):2148-51. PubMed ID: 3948186
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
3. Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC.
Gouyette A; Ducret JP; Caillé P; Amiel JL; Rouëssé J; Foka M; Carde P; Hayat M; Sancho-Garnier H
Anticancer Res; 1986; 6(5):1127-32. PubMed ID: 3800320
[TBL] [Abstract][Full Text] [Related]
4. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
Curt GA; Grygiel JJ; Corden BJ; Ozols RF; Weiss RB; Tell DT; Myers CE; Collins JM
Cancer Res; 1983 Sep; 43(9):4470-3. PubMed ID: 6347373
[TBL] [Abstract][Full Text] [Related]
5. [Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)].
Ota K; Wakui A; Majima H; Niitani H; Inuyama Y; Ogawa M; Ariyoshi Y; Yoshida O; Taguchi T; Kimura I
Gan To Kagaku Ryoho; 1992 Jun; 19(6):855-61. PubMed ID: 1605663
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of iproplatin (CHIP).
Creaven PJ; Pendyala L; Madajewicz S
Drugs Exp Clin Res; 1986; 12(1-3):287-92. PubMed ID: 3732051
[TBL] [Abstract][Full Text] [Related]
7. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP).
Creaven PJ; Madajewicz S; Pendyala L; Mittelman A; Pontes E; Spaulding M; Arbuck S; Solomon J
Cancer Treat Rep; 1983 Sep; 67(9):795-800. PubMed ID: 6883356
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.
Van Echo DA; Egorin MJ; Whitacre MY; Olman EA; Aisner J
Cancer Treat Rep; 1984 Sep; 68(9):1103-14. PubMed ID: 6383605
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP).
Mathé G; Kidani Y; Triana K; Brienza S; Ribaud P; Goldschmidt E; Ecstein E; Despax R; Musset M; Misset JL
Biomed Pharmacother; 1986; 40(10):372-6. PubMed ID: 3580505
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
12. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
Perez-Soler R; Lopez-Berestein G; Lautersztain J; al-Baker S; Francis K; Macias-Kiger D; Raber MN; Khokhar AR
Cancer Res; 1990 Jul; 50(14):4254-9. PubMed ID: 2364384
[TBL] [Abstract][Full Text] [Related]
16. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
18. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
[TBL] [Abstract][Full Text] [Related]
19. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
20. [Second-generation cisplatin analogs].
Ariyoshi Y; Ota K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1043-50. PubMed ID: 3551846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
